



For registration see NES website:
www.epilepsiselskapet.no

Satelite symposium in collaboration with NES.

1st Nordic Status Epilepticus Meeting **Bergen, 18 June 2020**

Haukeland University Hospital
Bikuben

The meeting is financially supported by Desitin.

Speakers and chairpersons




Eugen Trinka

MD, MSc, FRCP. Professor and Chair of the Department of Neurology, Christian Doppler University Hospital at the Paracelsus Medical University, Salzburg, Austria. Dean of Paracelsus Medical University of Salzburg. Current President of the Austrian Society of Neurology.

Prof Trinka is a world leading expert in clinical epileptology with research interests including epidemiology, prognosis, epilepsy surgery, and status epilepticus (SE), as well as clinical neurophysiology and functional neuroimaging. He is founding member of the European Epilepsy Consortium, dedicated to clinical drug trials in the field of epilepsy and has authored more than 450 scientific publications and book chapters.

With respect to SE, he was the initiator, together with prof Simon Shorvon, to the biannual landmark conferences on SE (The London Innsbruck Colloquia). He also serves on the ILAE Task force of Classification of SE responsible for the newly updated definitions and classification of SE.




Andrea Rossetti

is head of the EEG/epileptology unit at the Neurology Department of the CHUV (Lausanne University Hospital, Switzerland). His research has focused over several years upon nosology, diagnosis and treatment of status epilepticus; further interests are coma prognostication and pharmacological treatment of epilepsy.



Monika Mochol

PhD student, working as a consultant at the Østfold Hospital Trust. She is investigating the presence and role of immunological mechanisms in epilepsy patients.



Ketil Berg Olsen

Senior Consultant in Neurology and Clinical Neurophysiology, Østfold Hospital Trust and Oslo University Hospital, Rikshospitalet. Member of ERGO, Epilepsy Research Group of Oslo. Many years experience in epileptology/neurology/clinical neurophysiology, about 5 years experience in SEEG and IOM.



Ellen Molteberg

MD, Neurologist and Head of the Adult Department at the National Center for Epilepsy in Norway. Special interest in non-medical treatment, i.e. modified Atkins diet for adult patients.



Jon Barlinn

MD Senior consultant in Child Neurology Department of Pediatrics and Adolescent Medicine, Oslo University Hospital. The Child Neurology section at our hospital is treating super refractory epilepsy as a referral center. Ketogenic diet is one of our treatment modalities.



Gro Anita Gauslå

specialist in paediatric, working as a consultant at Department of Paediatric Neurology, OUS, Ullevål. Member of ERGO (Epilepsy Research Group of Oslo). Director Norwegian Headache Association.



Toni Berger

MD, PhD student, Department of Neurology, Oslo University Hospital - Rikshospitalet, Oslo, Norway. After working one year in the Department of Neurology, Østfold hospital trust, he joined ERGO (Epilepsy Research Group of Oslo in Department of Neurology, OUS-RH) in 2017. His PhD is financed by a Marie-Curie scholarship as part of the "EU Glia PhD" project - a European network for brain research.



Erik Taubøll

Professor of Neurology and Senior Consultant, Department of Neurology, Oslo University Hospital - Rikshospitalet, Oslo, Norway. Head of ERGO, Epilepsy Research Group of Oslo, in Department of Neurology. The group is active in both clinical, translational and basic epilepsy research, see: <https://www.ous-research.no/ergo/>



Bernt Engelsen

Born 1951. Professor of Neurology since 1989. Research background; neurotransmission research on glutamate in the 1980ies-90ies, and since 1994 head of the clinical epilepsy unit at Haukeland University Hospital. Research interest; clinical epileptology, POLG related epilepsy and Status epilepticus.



Line Bédos Ulvin

is a neurologist and clinical neurophysiologist working at Oslo University Hospital. Her field of interest is epilepsy and EEG, and she is involved in several research projects on status epilepticus.



Anette Storstein

MD PhD, is a consultant of neurology and vice chair of the Department of Neurology at Haukeland University Hospital. Her clinical and scientific focus is on neuroimmunology/ neuro-oncology and neurodegenerative diseases. As Chair of the Norwegian Brain Council, she works to improve and promote neuroscience and brain health issues.



Morten Horn

MD, PhD, is a consultant in neurology at Oslo University Hospital. He is a lecturer in medical ethics at the University of Oslo, and a member of the Medical Ethics Council for the Norwegian Medical Association.



Sarah Folkestad Habhab

is a medical student at the University of Southern Denmark. In her master's thesis, she has looked at the phenomenon of ammonia increase after intravenous valproic acid in a status epilepticus cohort, and assessed the impact of ammonia levels on treatment decisions. The work was done in collaboration with ERGO (Epilepsy Research Group of Oslo)



Tom Eichele

PhD is the head of clinical neurophysiology at the Haukeland university hospital in Bergen and current chairman of the Norwegian society for clinical neurophysiology. He has done extensive research on human electrophysiology and multimodal neuroimaging, and among his clinical main interests is neuromonitoring in epilepsy and critical care.



Kjersti Nesheim Power

is a neurologist with a PhD in cognitive consequences of status epilepticus. She is a member of Bergen Epilepsy Research Group and works in Olaviken Memory Clinic in Bergen.



Christian Samsonsen

Head of Department/neurologist, Department of Neurology and Clinical Neurophysiology, St Olav's hospital Associate professor, INB, NTNU. Special fields of interest: Clinical epileptology, seizure precipitants.



Dag Aurlien

Senior consultant MD PhD Dag Aurlien, Department of Neurology, Stavanger University Hospital. He has been active in SUDEP research for several years.

Program

10.00 Opening, *Erik Taubøll*

Definitions, mechanisms and diagnostic monitoring – chair **Bernt Engelsen**

10.10-10.55 Definitions, incidence and etiology. *Eugen Trinka*

10.55-11.15 Basic mechanisms for epileptogenesis and development of SE. *Toni Berger*

11.15-11.45 What is the role of EEG in SE? *Tom Eichele*

11.45-11.55 Discussion

12.00-13.00 **LUNCH**

Treatment of SE – chair **Christian Samsonsen**

13.00-13.20 The Norwegian guidelines for first-line treatment – are they followed? *Ketil Berg Olsen*

13.20-14.15 Refractory and superrefractory SE - which therapeutic strategy to choose when standard treatment does not work? *Andrea Rossetti*

14.15-14.40 **Coffee break**

When backs are against the wall: The Norwegian experience with non-standardized treatments – chair **Dag Aurlien**

14.40-15.00 Ketogenic diet. *Jon Barlinn*

15.00-15.15 Case report - the use of an interleukin 1 β antagonist-Anakinra. *Monika Mochol*

15.15-15.30 Pyridoxine in SE treatment – a case report. *Ellen Molteberg*

15.30-15.45 The sad story of neurosteroids – what can we learn from it? *Erik Taubøll*

15.45-16.05 **Coffee break**

SE in special syndromes and conditions – chair **Ellen Molteberg**

16.05-16.35 Autoimmune refractory epilepsy and SE. *Anette Storstein*

16.35-16.55 FIRES/NORSE. *Gro Anita Gauslå*

16.55-17.10 Hyperammonemia after VPA in SE – a clinical problem? *Sarah Habhab*

17.10-17.35 **Coffee, fruit**

Consequences of SE and ethical considerations – chair **Erik Taubøll**

17.35-18.00 Cognitive sequelae after SE. *Kjersti Nesheim Power*

18.00-18.20 Prediction of outcome. *Line Bédos Ulvin*

18.20-18.45 Ethical issues - when to stop SE treatment. *Morten Horn*

18.45-19.00 Closing remarks. What is the way forward in Norway? The need for a national SE registry. *Erik Taubøll*

